Home/Pipeline/CNTY-107

CNTY-107

Multiple Myeloma

PreclinicalResearch

Key Facts

Indication

Multiple Myeloma

Phase

Preclinical

Status

Research

Company

Century Therapeutics

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company developing allogeneic, iPSC-derived cell therapies for oncology and autoimmunity. Its core strategy is to utilize a renewable master iPSC bank, combined with precision genetic engineering, to create standardized, scalable, and readily available therapeutic products. Key achievements include advancing its lead CNTY-101 program into Phase 1 trials for B-cell malignancies and securing strategic collaborations with Bristol Myers Squibb and Bayer. The company's long-term vision is to establish iPSC-derived cell therapies as a mainstream, accessible treatment modality.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Multiple Myeloma Drugs

Drug	Company	Phase	Status
Tasquinimod	Active Biotech	Preclinical	Active (Academic Partnership)
Measovir®-based candidate	Oncovita	Pre-clinical	Preclinical activity demonstrated
Kyprolis® (carfilzomib)	Cleo Life Sciences	Approved	Supported late-stage development & NDA
inobrodib (CCS1477)	CellCentric	Phase 1/2	Active
ISB 2001	Ichnos Glenmark Innovation	Phase 1b	Active
In Vivo Cell Therapy	GigaMune	Pre-clinical	Active
Hemady	Dexcel Pharma USA	Approved	Commercial
AV-353	AVEO Oncology	Pre-clinical	Active
Sequesta™	ID4Pharma	Pre-clinical	Active
Myeloma Consortium	Criterium	Unknown	Active
GPRC5D x CD3 TCE	Integral Molecular	Preclinical	Available for License
RORA-Tscm CAR-T	RORABio	Pre-clinical	Active